Friday, 16 October 2026European Markets

MAGNORA And 2 Other Stocks Have High Sales Growth And An Above 3% Return on Equity

Loading stream...

(VIANEWS) - MAGNORA (MGN.OL), ING GROEP N.V. (INGA.AS), SPAREBANK 1 SØRØ (SOON.OL) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. MAGNORA (MGN.OL)

1022.8% sales growth and 10.56% return on equity

Magnora ASA operates as a renewable energy development company. It primarily focuses on developing wind and solar photovoltaic (PV) projects. The company also hold license agreements with the Dana Western Isles and Shell Penguins FPSO. It serves oil companies and marine contractors in the United Kingdom, Norway, and Sweden. The company was formerly known as Sevan Marine ASA and changed its name to Magnora ASA in October 2018. Magnora ASA was incorporated in 2001 and is based in Oslo, Norway.

Earnings Per Share

As for profitability, MAGNORA has a trailing twelve months EPS of kr0.75.

PE Ratio

MAGNORA has a trailing twelve months price to earnings ratio of 37.47. Meaning, the purchaser of the share is investing kr37.47 for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.56%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 331.6%, now sitting on 104.3M for the twelve trailing months.

Moving Average

MAGNORA's worth is above its 50-day moving average of kr26.44 and way above its 200-day moving average of kr23.49.

Earnings Before Interest, Taxes, Depreciation, and Amortization

MAGNORA's EBITDA is 16.77.

Volume

Today's last reported volume for MAGNORA is 60931 which is 80.09% below its average volume of 306113.

More news about MAGNORA.

2. ING GROEP N.V. (INGA.AS)

24.2% sales growth and 25.17% return on equity

ING Groep N.V., a financial institution, provides various banking products and services in the Netherlands, Belgium, Rest of Europe, North America, Latin America, Asia, and Australia. It operates in six segments: Retail Netherlands, Retail Belgium, Retail Germany, Retail Other, Wholesale Banking, and Corporate Line Banking. The company accepts various deposits, such as current and savings accounts. It also offers business lending products; consumer lending products, such as residential mortgage loans, term loans, and other consumer lending loans; and secured and unsecured lending services. in addition, the company provides debt capital market, working capital solutions, export finance, daily banking, treasury and risk, and corporate finance solutions; and specialized lending, debt and equity market solutions, payments and cash management, and trade and treasury services, as well as savings, investment, insurance, mortgage, and digital banking services; and SME loans. It serves individual customers, corporate clients, and financial institutions. ING Groep N.V. was founded in 1762 and is headquartered in Amsterdam, the Netherlands.

Earnings Per Share

As for profitability, ING GROEP N.V. has a trailing twelve months EPS of €1.34.

PE Ratio

ING GROEP N.V. has a trailing twelve months price to earnings ratio of 9.25. Meaning, the purchaser of the share is investing €9.25 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 25.17%.

More news about ING GROEP N.V..

3. SPAREBANK 1 SØRØ (SOON.OL)

18.8% sales growth and 10.73% return on equity

SpareBank 1 Sørøst-Norge provides various banking products and services for private and corporate customers in Norway. The company offers mobile and online banking, card, account, and payment services. It also provides mortgage, car, boat, consumer, and other vehicle loans as well as refinancing, micro savings, investment, pension, and property related services. In addition, the company offers daily operations, get paid, loans and financing, and pension related products. Further, it provides business and personnel insurance as well as savings and investment products. The company was founded in 1859 and is headquartered in Sandefjord, Norway.

Earnings Per Share

As for profitability, SPAREBANK 1 SØRØ has a trailing twelve months EPS of kr4.81.

PE Ratio

SPAREBANK 1 SØRØ has a trailing twelve months price to earnings ratio of 10.4. Meaning, the purchaser of the share is investing kr10.4 for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.73%.

Dividend Yield

As stated by Morningstar, Inc., the next dividend payment is on Mar 31, 2023, the estimated forward annual dividend rate is 2.6 and the estimated forward annual dividend yield is 5.16%.

Yearly Top and Bottom Value

SPAREBANK 1 SØRØ's stock is valued at kr50.00 at 17:20 EST, way below its 52-week high of kr57.40 and above its 52-week low of kr47.40.

Growth Estimates Quarters

The company's growth estimates for the present quarter and the next is 40.9% and 37.3%, respectively.

More news about SPAREBANK 1 SØRØ.

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com